The international surgical journal with global reach

Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol 2020; 5: 658-666.

Published: 17th November 2020

Authors: Andreson V, Gschossmann J, Layer P

Conclusion

A total of 443 patients were involved: active treatment was given for eight weeks. A composite endpoint including a 30 per cent improvement in pain relief, and relief of irritable bowel syndrome symptoms, was reached in 34 per cent of treated versus 19 per cent of control patients, P=0.0007.

Pubmed Link